Marisa E Mcgrath

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5961525/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine, 2020, 383, 2320-2332.	27.0	1,000
2	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020, 370, .	12.6	508
3	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nature Microbiology, 2021, 6, 1233-1244.	13.3	237
4	A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nature Biomedical Engineering, 2021, 5, 815-829.	22.5	228
5	Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications, 2021, 12, 6055.	12.8	215
6	Coronavirus interactions with the cellular autophagy machinery. Autophagy, 2020, 16, 2131-2139.	9.1	113
7	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Reports Medicine, 2021, 2, 100405.	6.5	110
8	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine, 2022, 14, .	12.4	57
9	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Cell, 2022, 185, 614-629.e21.	28.9	40
10	The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30687-30698.	7.1	22
11	Host Cell Glycocalyx Remodeling Reveals SARS-CoV-2 Spike Protein Glycomic Binding Sites. Frontiers in Molecular Biosciences, 2022, 9, 799703.	3.5	11
12	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Science Translational Medicine, 2021, , eabj5305.	12.4	4
13	Collaboration between the Fab and Fc Contribute to Maximal Protection Against SARS-CoV-2 Following NVX-CoV2373 Subunit Vaccine with Matrix-Mâ"¢ Vaccination. SSRN Electronic Journal, 0, , .	0.4	1